Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6518-6526

  Loprevite, Maura ^a   Tiseo, Marcello ^b   Chiaramondia, Maurizio ^a   Capelletti, Marzia ^b   Bozzetti, Cecilia ^b   Bortesi, Beatrice ^b   Naldi, Nadia ^b   Nizzoli, Rita ^b   Dadati, Patrizia ^a   Kunkl, Annalisa ^a   Zennaro, Daniela ^a   Lagrasta, Costanza ^b   Campanini, Nicoletta ^b   Spiritelli, Elena ^b   Camisa, Roberta ^b   Grossi, Francesco ^a   Rindi, Guido ^b   Franciosi, Vittorio ^b   Ardizzoni, Andrea ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ACNE; ADULT; AGED; ARTICLE; CHEEK MUCOSA; DRUG ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MOUTH MUCOSA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 35948981196     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0805     Document Type: Article

References (31)

1. Bunn PAJ, Franklin WA. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29:38-44.
2. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005;23:3235-42.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-58.
5. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with Erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004;22:3238-47.
6. Bunn PA, Jr., Dziadziuszko R, Varella-Garcia M, et al. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 2006;12:3652-6.
7. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
8. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA, Jr. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why, when, and how? Clin Cancer Res 2006;12:4409-15s.
9. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41.
10. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation innon-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:493-501.
11. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
12. Adjei AA, Erlichman C, Davis JN, et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-7.
13. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:1760-6.
14. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46.
15. Brandt B, Meyer-Staeckling S, Schmidt H, et al. Mechanisms of EGFR gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 2006;12:7252-60.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
17. Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003;39:1242-50.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
20. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
21. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in K-ras are predictive and prognostic indicators in patients with non small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900- 9.
22. Spector NL, Xia W, Burris H III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
23. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003;9:2478-86.
24. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-33.
25. Rothenberg ML, La Fleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-74.
26. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-16.
27. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807.
28. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ("Iressa", ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91:208-12.
29. Bailey L, Janas M, Schmidt N, et al. Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy (abstract 7013). Proc Am Soc Clin Oncol 2004;22:618.
30. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
31. Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006;12:4416-20s.